Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Notice of Annual General Meeting for Prevas AB

Unofficial English translation for information purposes only. If there are differences between the English translation and the Swedish original, the Swedish text will take precedence. The shareholders of Prevas AB, corporate registration number 556252-1384, are hereby given notice of the Annual General Meeting to be held on Wednesday May 15, 2024, at 6 p.m. in the company’s premises at Glödgargränd 14, Västerås, Sweden. RIGHT TO PARTICIPATE Shareholders wishing to attend the Annual General Meeting must: · partly be registered as shareholders in the share register held by

Checkin.com Group publishes Annual Report 2023

Checkin.com Group (STO:CHECK) today publishes its Annual Report for the financial year 2023. The Annual Report is attached to this press release and available on the company’s website: https://group.checkin.com/investors/reports/For further information, please contact: Jonas Köpniwsky, Head of Communications Checkin.com Group, press@checkin.com Certified Adviser Checkin.com Group’s Certified Adviser is Carnegie Investment Bank AB (publ). About Checkin.com Group Checkin.com Group creates shareholder value through capital efficient growth achieved by strong organic growth

Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the Canadian authorities issued a patent for the drug candidate CS1:s second patent family on Tuesday April 9. This strengthens and expands the immaterial rights (IPR) for Cereno’s drug candidate CS1, which is currently in clinical Phase II development as a treatment of the rare disease Pulmonary Arterial Hypertension (PAH).“I am pleased to announce that we have secured further immaterial rights for the drug candidate CS1 in

Initial data presented from the Investigator Initiated Trial (IIT) at Radboud University Medical Center using the CLS TRANBERG[®] system

Lund, Sweden April 11, 2024 – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announces that for the first-time clinical data has been presented from the investigator-initiated study at Radboud University Medical Center in Nijmegen, the Netherlands, on the use of CLS’s MR-guided TRANBERG® system for Focal Laser Ablation (FLA) of localized prostate cancer.During the ECR (European Congress of Radiology) annual meeting in Vienna, Austria, an abstract by the principal investigator for the ongoing study at Radboud University Medical Center (RUMC), Prof. Jurgen Fütterer and

Fiskars Corporation to publish its Interim Report for January-March 2024 on April 25, 2024

Fiskars CorporationPress ReleaseApril 11, 2024 at 9.30 a.m. EEST Fiskars Corporation to publish its Interim Report for January-March 2024 on April 25, 2024 Fiskars Corporation will publish its Interim Report for January-March 2024 on April 25, 2024 at approximately 8:30 a.m. (EEST). The Interim Report will be available on the company's website www.fiskarsgroup.com after publication. Webcast A webcast on the first quarter results will be held on April 25, 2024 at 1:00 p.m. (EEST). It will be held in English and can be followed at https://fiskars.videosync.fi/q1-2024

Remedy Entertainment Plc: Share subscriptions based on stock options 2018 and 2019

Remedy Entertainment Plc       Stock exchange release          April 11, 2024, 9.30 a.m. EEST   Share subscriptions based on stock options 2018 and 2019 Between January 1 and March 31, 2024, a total of 36,250 Remedy Entertainment Plc’s new shares has been subscribed for with the company’s stock options 2018 and 2019. For subscriptions made with the stock options 2018 and 2019, the entire subscription price of EUR 261,105.00 will be entered in the reserve for invested unrestricted equity. After the trade registration the total amount of shares is 13,552,651. The shares

Invitation to Rottneros’ interim report for Q1 2024

The interim report for the first quarter 2024 will be published on 25 April 2024, at 8.00 CET, and is followed by a webcast live at 12.00 CET the same day.All participants can follow the presentation via the web link: Rottneros - Q1 Presentation 2024 - Finwire  Questions can be asked via the link in advance or during the presentation. You can also watch the presentation afterwards via Rottneros'  Youtube channel  and website: Reports and presentations | Rottneros 

Steady Energy and TVO Nuclear Services sign an agreement regarding nuclear power expertise services from Olkiluoto

TVO Nuclear Services (TVONS) and Steady Energy have signed a collaboration agreement related to the development of a nuclear heating plant, initially focusing on the planning of the nuclear facility’s operation and safety.The agreement gives Steady Energy access to Teollisuuden Voima Oyj’s (TVO) strong expertise in the planning and implementation of nuclear power plant projects as well as the operation, maintenance and service life management of the plants. Steady Energy aims to construct several 50-megawatt small modular reactors (SMRs) in Finland for the purpose of district heat

AbbVie’s AQUIPTA[®]▼(atogepant) Is Recommended By NICE For The Prevention Of Migraine In Adults

PRESS RELEASE - For UK consumer, medical and trade media only · The National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance (FDG) recommending AQUIPTA[®] (atogepant), the oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) as an option in suitable patients for preventing migraine in adults who have at least 4 migraine days per month, only if at least 3 preventative treatments have not worked.[1] Suitable patients will soon have the option to be prescribed atogepant on the NHS in England and Wales. · The NICE

Net Asset Value(s)

RIZE SUSTAINABLE FUTURE OF FOOD UCITS ETF (LEI: 635400XEUXEEYJDGAN37) Final Net Asset Value FUND NAME NAV ISIN NAV DATE RIZE SUSTAINABLE 3.9883 USD IE00BLRPQH01 10 April 2024FUTURE OF FOOD UCITS ETF RIZE CYBER SECURITY AND DATA PRIVACY UCITS ETF (LEI: 635400X9AIBDQQ6PQR51) Final Net Asset Value FUND NAME NAV­ ISIN NAV DATERIZE CYBER SECURITY AND 7.3248 USD IE00BJXRZJ40 10 April 2024DATA PRIVACY UCITS ETF RIZE DIGITAL PAY ECONOMY ETF (LEI: LEI 635400LYAWYIKLU7RN49) Final

AstraZeneca increases 2024 dividend by 7%

11 April 2024  AstraZeneca increases 2024 dividend by 7% AstraZeneca announced today that the Board intends to increase the annualised dividend for 2024 by $0.20 to $3.10 per share, underlining the company's confidence in its performance and cash generation. This takes into account other capital allocation priorities as well as previously announced acquisitions and business development. Michel Demaré, Chair, AstraZeneca said: "The Board is delighted to announce a 7% increase to the dividend, taking it to $3.10 per share. This uplift is in line with our progressive dividend policy,

Invitation to Electrolux Group Q1 presentation

Electrolux Group results for the first quarter of 2024 will be published on April 26, 2024, at approx. 08.00 CET.A telephone conference will be held following the release of the results, starting at 09.00 CET. Jonas Samuelson, President and CEO, and Therese Friberg, CFO, will comment on the report. Information on how to join the telephone conference is available HERE . Slides used in the presentation and report will be available at the Group’s website, www.electroluxgroup.com/ir.

Invitation to the presentation of John Mattson’s interim report Q1 2024 on 25 April at 11:00 am (CEST)

Invitation by John Mattson to the webcast and the teleconference on 25 April at 11:00 a.m. (CEST) being held in conjunction with the publication of the company’s interim report for January-March 2024 at 8:00 a.m. (CEST) the same date.Investors, asset managers, equity analysts, the press and other stakeholders are invited to participate in the presentation, where CEO Per Nilsson and acting CFO Ebba Pilo Karth will comment on the results for January-March 2024. Following the presentation, it will be possible to ask questions. The presentation will be given in Swedish and can be followed live

ABGSC to publish Q1 2024 Interim Report on 18 April

ABG Sundal Collier (“ABGSC”) will publish its Q1 2024 figures on 18 April 2024 at 08:00 CEST. The report will be available on our corporate website www.abgsc.com. Webcast presentation CEO Jonas Ström will present the Q1 results through a webcast at 09:00 CEST, followed by a Q&A session. The webcast presentation can be accessed through a web link or call-in details presented on our corporate website www.abgsc.com. For further information: Geir B. Olsen, CFO, +47 22 01 60 35 For media contacts: Anna Tropp, Head of Communications, +46 722 30 94 17

Elkem ASA - Invitation to first quarter 2024 results presentation

Oslo, 11 April 2024 Elkem ASA will release its report for the first quarter 2024 on Thursday, 18 April at 7.00 a.m. CET. The quarterly report and presentation material will be made available at this time at www.elkem.com In connection with the quarterly report, the company will host a presentation at 8.00 a.m. CET. The event will take place in Auditoriet, Haakon Vll gate 2, Oslo. The first quarter presentation can also be viewed in a live webcast at Elkem Webcast Q1 2024 (royalcast.com)  or via www.elkem.com The

Notice to the Annual General Meeting in GARO Aktiebolag (publ)

The shareholders of GARO Aktiebolag (publ) (“GARO” or the “Company”), Reg. No. 556051-7772, are hereby invited to attend the Annual General Meeting (the “AGM”) to be held at 5 p.m. CEST on 14 May 2024 at the Company’s premises on Järnvägsgatan 35 in Hillerstorp, Sweden. Registration will commence at 4.00 p.m. CEST. Welcome to attend a tour of GARO’s factory in Hillerstorp after the closing of the AGM.  A.                         RIGHT TO PARTICIPATE IN THE AGM A person who wishes to participate in the AGM must: firstly, be listed as a shareholder in the presentation of the

Konecranes’ Interim report, January–March 2024 will be published on April 25, 2024

KONECRANES PLC PRESS RELEASE April 11, 2024 at 09:00 AM EEST   Konecranes’ Interim report, January–March 2024 will be published on April 25, 2024   Konecranes will publish its Interim report, January-March 2024 on Thursday, April 25, 2024 at approximately 8:30 a.m. EEST. The report will be available on the company’s website at www.konecranes.com after publishing.   A live international webcast and telephone conference for analysts, investors and media will be arranged on the publishing day at 11:30 a.m. EEST. The event will be held in English. The Interim report will be

Kappahl announces major investment to develop a new distribution centre in Arendal

Storage and distribution facilities will be moved close to the Port of Gothenburg in 2026In order to future-proof its delivery and logistics operations as it continues its growth journey, Kappahl Group will be opening a new distribution centre in the industrial area of Arendal on the outskirts of Gothenburg. The new state-of-the-art facility, located adjacent to the Port of Gothenburg, is expected to be operational in the second half of 2026. "Our goal is to offer more of our strong brands via new markets and channels. To achieve this, our distribution centre must be able

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso

Metso Corporation’s stock exchange release on April 11, 2024, at 09:00 a.m. EESTMetso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the shareholding of BlackRock, Inc. On April 9, 2024, BlackRock's holding in Metso’s shares exceeded the 5 percent threshold and amounted to 41,626,742 shares or 5.02 percent of total shares and votes. BlackRock's holding through financial instruments in Metso amounted to 1,920,383 shares, which corresponds to 0.23 percent of the total amount of Metso’s shares. On

Image System's business area RemaSawco receives an order from a Canadian sawmill for SEK 1 million

RemaSawco AB has received an order from a Canadian sawmill regarding the upgrade of the sawmill's saw line. The order value amounts to SEK 1 million + commissioning costs.The order received from the Canadian sawmill concerns a modernization and upgrade of existing systems on the sawmill's saw line. The order mainly includes upgrading the existing 3D measuring frame and upgrading to the optimization system RS-Opt Sawline. In addition, the order includes a number of minor upgrades and training of the customer's staff on site. The order value amounts to SEK 1 million plus costs for

NOTICE OF ANNUAL GENERAL MEETING IN MICRO SYSTEMATION AB (publ)

The shareholders in Micro Systemation AB (publ), reg. no. 556244-3050, (“MSAB” or the “Company”) are hereby invited to the Annual General Meeting (“AGM”) on Tuesday 14 May 2024, at 19.00 CEST, at Cirio Advokatbyrå, Biblioteksgatan 9, in Stockholm. Registration for the AGM will commence at 18.15. The Board of Directors has resolved that shareholders shall have the right to exercise their voting rights in advance through postal voting pursuant to § 15 in the Company’s Articles of Associations. Therefore, shareholders may choose to exercise their voting rights at the AGM by attending by

Inify Laboratories - Annual Report 2023

Stockholm – April 11, 2024 – Inify Laboratories, a unique laboratory service provider within pathology and cancer diagnostics, presents its Annual Report for the fiscal year ended December 31, 2023. The annual report is attached to this press release and is also available on the company’s website: www.inify.com. Printed copies of the report will be distributed upon request sent to e-mail: ir@inify.com. For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: ann-charlotte.linderoth@inify.com or: ir@inify.com   ###     About Inify Laboratories Inify

Inify Laboratories – notice of Annual General Meeting on May 14, 2024

Stockholm – April 11, 2024 – Inify Laboratories AB (publ), a unique laboratory service provider within pathology and cancer diagnostics, hereby invites its shareholders to Annual General Meeting on May 14, 2024. Please find attached the invitation including agenda and details on how to register and vote. The invitation is also available on the company’s website: www.inify.com. For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: ann-charlotte.linderoth@inify.com or: ir@inify.com.   ###     About Inify Laboratories Inify Laboratories provides cancer

There are no items matching the current filter
There are no more items matching the current filter
Back to top